The stock of Kala Bio Inc (KALA) has gone up by 23.56% for the week, with a 14.73% rise in the past month and a 43.04% rise in the past quarter. The volatility ratio for the week is 11.54%, and the volatility levels for the past 30 days are 6.51% for KALA. The simple moving average for the past 20 days is 19.63% for KALA’s stock, with a 19.12% simple moving average for the past 200 days.
Is It Worth Investing in Kala Bio Inc (NASDAQ: KALA) Right Now?
KALA has 36-month beta value of -2.11. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for KALA is 3.77M, and currently, short sellers hold a 0.57% ratio of that float. The average trading volume of KALA on January 03, 2025 was 27.75K shares.
KALA) stock’s latest price update
Kala Bio Inc (NASDAQ: KALA)’s stock price has soared by 11.10 in relation to previous closing price of 6.94. Nevertheless, the company has seen a gain of 23.56% in its stock price over the last five trading days. globenewswire.com reported 2024-12-30 that ARLINGTON, Mass., Dec. 30, 2024 (GLOBE NEWSWIRE) — KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors for the sale, in a private placement, of shares of its common stock and shares of its Series I Convertible Non-Redeemable Preferred Stock (the “Series I Preferred Stock”), for aggregate gross proceeds of approximately $10.75 million, before deducting offering expenses.
Analysts’ Opinion of KALA
Jefferies gave a rating of “Hold” to KALA, setting the target price at $10 in the report published on September 14th of the previous year.
KALA Trading at 16.11% from the 50-Day Moving Average
After a stumble in the market that brought KALA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.65% of loss for the given period.
Volatility was left at 6.51%, however, over the last 30 days, the volatility rate increased by 11.54%, as shares surge +17.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +47.14% upper at present.
During the last 5 trading sessions, KALA rose by +23.56%, which changed the moving average for the period of 200-days by +0.13% in comparison to the 20-day moving average, which settled at $6.44. In addition, Kala Bio Inc saw 11.10% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KALA starting from BAKER BROS. ADVISORS LP, who purchase 310,559 shares at the price of $6.44 back on Dec 30 ’24. After this action, BAKER BROS. ADVISORS LP now owns 1,083,398 shares of Kala Bio Inc, valued at $2,000,000 using the latest closing price.
Bazemore Todd, the of Kala Bio Inc, sale 4,653 shares at $4.75 during a trade that took place back on Jun 26 ’24, which means that Bazemore Todd is holding 83,040 shares at $22,102 based on the most recent closing price.
Stock Fundamentals for KALA
Current profitability levels for the company are sitting at:
- -581.53 for the present operating margin
- -1.81 for the gross margin
The net margin for Kala Bio Inc stands at -556.61. The total capital return value is set at -1.35. Equity return is now at value -430.96, with -67.64 for asset returns.
Based on Kala Bio Inc (KALA), the company’s capital structure generated 0.84 points at debt to capital in total, while cash flow to debt ratio is standing at -0.91. The debt to equity ratio resting at 5.18. The interest coverage ratio of the stock is -6.95.
Currently, EBITDA for the company is -36.08 million with net debt to EBITDA at 0.37. When we switch over and look at the enterprise to sales, we see a ratio of 334.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.15.
Conclusion
To put it simply, Kala Bio Inc (KALA) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
